Biophore ramps up Made-In-India
Favipiravir production for Covid-19
News Desk, News Nation 360: Biophore India Pharmaceuticals has announced that it has successfully completed the validation of favipiravir and scaled-up its production. Favipiravir is the active pharmaceutical ingredient (API) that can be used in the finished formulation of an antiviral drug approved by the Drug Controller General of India (DCGI) for mild to moderate cases of Covid-19. Favipiravir is an antiviral agent that was initially discovered and developed because of its activity against another
RNA virus, the influenza virus. Apart from India and Turkey, it has already been approved for use against Covid-19 in Russia and parts of the Middle East and advanced stage trials are currently underway in other parts of the world. Biophore has received the DCGI license to manufacture the API in India and has been cleared for export as well. It has also received approval in Turkey in collaboration with a local Turkish partner. Additionally, the company is in talks with several Indian partners to commercialize the product in India and with Bangladesh and Egypt-based companies for its export. Dr Manik Reddy Pullagurla, Founder and Chief Scientific Officer (CSO) of Biophore, told the Covid-19 pandemic has emphasized the need for pharmaceutical companies to step up and develop effective solutions quickly, without compromising on safety. They have ensured that their favipiravir meets the highest standards of quality. Their manufacturing facilities comply with US and EU regulations and they have stringent internal impurity controls and quality checks to ensure that. Meeting favipiravir needs in India is their priority, and they have the capacity to scale up production of favipiravir to meet local requirements, without compromising on their export commitments. Dr Jagadeesh Babu Rangisetty, CEO at Biophore, told in line with Prime Minister Narendra Modi’s call to Make in India, and become vocal for local, he is proud to say that Biophore’s favipiravir is 100% Made in India. This is what sets us apart from many other suppliers of this API. They are not dependent on any imports to produce favipiravir. All starting materials and complex intermediates are either sourced locally or have been developed in-house for use. They are confident that this API will help their country move several steps forward in their united fight against Covid-19. Biophore is also awaiting DCGI approval for a favipiravir finished dosage form.
Report : Anustup Kundu